Pharmaceuticals company Laurus Labs announced Q3FY25 results 9MFY25 Revenues Rs 3,834 crore and 6% revenue growth, performance on track to deliver Full Year growth outlook with Q4 revenues accelerating on planned project deliveries. Rs 638 crore EBITDA resulted in a margin of 16.6%, improved steadily with the gradual step-up in the asset utilization. Gross margins maintained at healthy levels 55.8%, improving 3.3% pts over last year on positive product mix. Q3FY25 Revenues Rs 1,415 crore; +18 revenue growth, Rs 285 crore EBITDA; +56% growth resulted in a margin of 20.1%, Gross margins were at 56.9%. Strengthening operational performance in CMO/CDMO with continued demand for complex API capabilities. CAPEX investments in key growth projects are on track to support long term growth. FY25 outlook retained; Revenue growth and EBITDA margins improvement, led by execution on few late-phase clinical projects along with reduction in net debt. Satyanarayana Chava, Founder & Chief Executive Officer, said: “Q3FY25 operating performance has improved progressively; we have delivered healthy growth, driven by growing demand for our platform capabilities, effectively addressing evolving customer needs. The quarter witnessed robust growth in the CDMO and FDF division, partially offset by soft API performance. Healthy commercial execution is our top priority and our performance is well on track with revenues accelerating in Q4. Based on our continued progress acroreoss diverse portfolio and pipeline projects I remain confident about our long-term future, and I acknowledge the focus and commitment of our team in making Laurus better positioned to deliver value to all stakeholder in coming years.” V V Ravi Kumar, Executive Director & Chief Financial Officer, said: “We are pleased to report healthy progress for the quarter; we delivered Rs 1,415 crore in revenues, strong growth of 18% and Rs 285 crore EBITDA grew by 56%, resulting in 20.1% margin. Gross margins remained healthy at 56.9% due to favorable CDMO mix and process optimization measures. The fundamentals of our business remain healthy, driven by order book position and continued progress in CDMO projects. Our 9MFY25 performance remain on track, with revenues reaching Rs 3,834 crore, representing 6% growth and EBITDA stood at Rs 638 crore, marking growth of 18%. The EBITDA margin of 16.6% has improved, supported by gradual ramp-up in the assets utilization rates. We reaffirm our Full year growth outlook, driven by scheduled CDMO project deliveries. Our capital allocation strategy remain unchanged, prioritizing investments into high value CMO/CDMO opportunities to drive near and long-term growth.” Result PDF